Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Synopsys Inc is a software-infrastructure business based in the US. Synopsys shares (SNPS) are listed on the NASDAQ and all prices are listed in US Dollars. Synopsys employs 16,361 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $301.23 |
|---|---|
| 52-week range | $255.02 - $377.60 |
| 50-day moving average | $298.06 |
| 200-day moving average | $317.28 |
| Wall St. target price | $382.49 |
| PE ratio | 46.558 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $6.47 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $301.23 from 2022-07-01
| 1 week (2022-06-28) | -0.80% |
|---|---|
| 1 month (2022-06-02) | -8.94% |
| 3 months (2022-04-05) | -8.08% |
| 6 months (2022-01-05) | -11.34% |
| 1 year (2021-07-02) | 7.91% |
|---|---|
| 2 years (2020-07-02) | 52.46% |
| 3 years (2019-07-05) | 122.47% |
| 5 years (2017-07-05) | 314.12% |
Valuing Synopsys stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Synopsys's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Synopsys's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 47x. In other words, Synopsys shares trade at around 47x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Synopsys's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.0961. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Synopsys's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Synopsys's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.3 billion.
The EBITDA is a measure of a Synopsys's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $4.8 billion |
|---|---|
| Operating margin TTM | 24.13% |
| Gross profit TTM | $3.4 billion |
| Return on assets TTM | 8.18% |
| Return on equity TTM | 18.81% |
| Profit margin | 21.19% |
| Book value | $36.38 |
| Market capitalisation | $46.1 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Synopsys.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 21.54
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Synopsys's overall score of 21.54 (as at 12/31/2018) is excellent – landing it in it in the 14th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Synopsys is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 9.6/100
Synopsys's environmental score of 9.6 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Synopsys is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 14.57/100
Synopsys's social score of 14.57 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Synopsys is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 9.87/100
Synopsys's governance score puts it squarely in the 9th percentile of companies rated in the same sector. That could suggest that Synopsys is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Synopsys Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 21.54 |
|---|---|
| Total ESG percentile | 14.2 |
| Environmental score | 9.6 |
| Environmental score percentile | 9 |
| Social score | 14.57 |
| Social score percentile | 9 |
| Governance score | 9.87 |
| Governance score percentile | 9 |
We're not expecting Synopsys to pay a dividend over the next 12 months.
Synopsys's shares were split on a 2:1 basis on 23 September 2003. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Synopsys shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Synopsys shares which in turn could have impacted Synopsys's share price.
Over the last 12 months, Synopsys's shares have ranged in value from as little as $255.02 up to $377.6. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Synopsys's is 1.1987. This would suggest that Synopsys's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Synopsys, Inc. provides electronic design automation software products used to design and test integrated circuits. The company offers Fusion Design Platform that provides digital design implementation solutions; Verification Continuum Platform that provides virtual prototyping, static and formal verification, simulation, emulation, field programmable gate array (FPGA)-based prototyping, and debug solutions; and FPGA design products that are programmed to perform specific functions. It also provides intellectual property (IP) solutions for USB, PCI Express, DDR, Ethernet, SATA, MIPI, HDMI, and Bluetooth low energy applications; analog IP, including data converters and audio codecs; and system-on-chip (SoC) infrastructure IP, datapath and building block IP, and verification IP products, as well as mathematical and floating-point components, and Arm AMBA interconnect fabric and peripherals. In addition, the company offers logic libraries and embedded memories; configurable processor cores and application-specific instruction-set processor tools for embedded applications; IP subsystems for audio, sensor, and data fusion functionality; and security IP solutions. Further, it provides Platform Architect solutions for SoC architecture analysis and optimization; virtual prototyping solutions; and HAPS FPGA-based prototyping systems, as well as a series of tools used in the design of optical systems and photonic devices. Additionally, the company offers security testing, managed services, programs and professional services, and training that enable its customers to detect and remediate security vulnerabilities, and defects in the software development lifecycle, as well as manufacturing solutions.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.